COMBINATION OF SORAFENIB AND 5-AZACYTIDINE HAS SIGNIFICANT ACTIVITY IN PATIENTS WITH RELAPSED/REFRACTORY OR UNTREATED ACUTE MYELOID LEUKEMIA AND FLT3-ITD MUTATION

被引：0
|
作者：
Ravandi, Farhad [1 ]
Alattar, Mona Lisa [1 ]
Levis, Mark [1 ]
Garcia-Manero, Guillermo [1 ]
Richie, Mary A. [1 ]
Daver, Naval [1 ]
Faderl, Stefan [1 ]
Borthakur, Gautam [1 ]
Burger, Jan [1 ]
Kadia, Tapan [1 ]
Grunwald, Michael [1 ]
Dellasala, Sara [1 ]
Cortes, Jorge [1 ]
Kantarjian, Hagop [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF HEMATOLOGY | 2013年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
45
引用
收藏
页码：S19 / S20
页数：2
相关论文
共 50 条
  • [31] Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations
    Scholl, Sebastian
    Spies-Weisshart, Baerbel
    Klink, Anne
    Muegge, Lars-Olof
    Fricke, Hans-Joerg
    Hochhaus, Andreas
    ANNALS OF HEMATOLOGY, 2011, 90 (04) : 473 - 475
  • [32] Prognostic value of the mutation types and dynamics of FLT3-ITD in acute myeloid leukemia
    Koo, Mosae
    Song, Ik-Chan
    Kim, Jimyung
    Kwon, Gye Cheol
    Kim, Seon Young
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (04) : 562 - 572
  • [33] Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy
    Sid, Selim
    Rey, Jerome
    Charbonnier, Aude
    D'Incan, Evelyne
    Mohty, Bilal
    Blaise, Didier
    Vey, Norbert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (04) : 241 - 242
  • [34] Sorafenib Plus Triplet Therapy with Venetoclax, Azacitibine and Homoharringtonine for Refractory/Relapsed Acute Myeloid Leukemia with FLT3-ITD: A Multicentre, Phase 2 Study
    Yu, Sijian
    Liu, Qifa
    Zhang, Yu
    Yu, Guopan
    Wang, Yu
    Shao, Ruoyang
    Liu, Qiong
    BLOOD, 2023, 142
  • [35] The Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia
    Li, Xia
    Yin, Xiufeng
    Wang, Huafeng
    Huang, Jiansong
    Yu, Mengxia
    Ma, Zhixin
    Li, Chenying
    Zhou, Yile
    Yan, Xiao
    Huang, Shujuan
    Jin, Jie
    BLOOD, 2016, 128 (22)
  • [36] The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
    Li, Xia
    Yin, Xiufeng
    Wang, Huafeng
    Huang, Jiansong
    Yu, Mengxia
    Ma, Zhixin
    Li, Chenying
    Zhou, Yile
    Yan, Xiao
    Huang, ShuJuan
    Jin, Jie
    ONCOTARGET, 2017, 8 (08) : 12764 - 12774
  • [37] A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation
    Pratz, Keith W.
    Rudek, Michelle A.
    Smith, B. Douglas
    Karp, Judith
    Gojo, Ivana
    Dezern, Amy
    Jones, Richard J.
    Greer, Jackie
    Gocke, Christopher
    Baer, Maria R.
    Duong, Vu H.
    Rosner, Gary
    Zahurak, Marianna
    Wright, John J.
    Emadi, Ashkan
    Levis, Mark
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (02) : 300 - 306
  • [38] Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations
    Sebastian Scholl
    Baerbel Spies-Weisshart
    Anne Klink
    Lars-Olof Muegge
    Hans-Joerg Fricke
    Andreas Hochhaus
    Annals of Hematology, 2011, 90 : 473 - 475
  • [39] FLT3-ITD As a Prognostic Factor for Chinese Patients with Acute Myeloid Leukemia
    Sun, Jie
    He, Jingsong
    Wei, Guoqing
    Zheng, Weiyan
    Shi, Jimin
    Luo, Yi
    Huang, He
    BLOOD, 2016, 128 (22)
  • [40] Pretreatment FMS like Tyrosine kinase-3 Internal Tandem duplication (FLT3-ITD) Mutant Allele Burden Does Not Predict Response to the Combination of Sorafenib and Azacytidine in Patients with Relapsed or High Risk Elderly Untreated Acute Myeloid Leukemia
    George, Binsah
    Cortes, Jorge
    Cabrera, Monica
    Jain, Nitin
    Konopleva, Marina
    Andreeff, Michael
    Tapan, Kadia
    Pierce, Sherry
    Dellasala, Sara
    Borthakur, Gautham
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    Ravandi, Farhad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S196 - S197
12345